生物疫苗股全線上漲 世衞組織將推加速新冠疫苗研發新方案
格隆匯4月7日丨A股生物疫苗股集體大漲,其中,未名醫藥和新開源漲停,康泰生物漲超8%,舒泰神、生物股份漲超7%,九強生物、魯抗醫藥、戴維醫療、四環生物等漲超5%。
昨日消息顯示,世衞組織將推出有關加速新冠疫苗研發的新方案,並建立相應機制以確保疫苗問世後能在全球範圍內得到公平分配。世衞組織總幹事譚德塞稱,世衞組織有望最快於本週內宣佈一項加速新冠疫苗研發和生產的“大型方案”。屆時,這項方案將由來自發達國家和發展中國家的高級研究人員共同參與。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.